SPARC ameliorates ovarian cancer-associated inflammation

Neveen A. Said, Ahmed Abdelrazik Elmarakby, John D. Imig, David J Fulton, Kouros Motamed

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

We have recently identified that the role of secreted protein acidic and rich in cysteine (SPARC) in amelioration of peritoneal ovarian carcinomatosis is mediated, at least in part, through mesothelial cell/lysophosphatidic acid-induced inflammatory response in ovarian cancer cells. The aim of this study was to elucidate the molecular mechanisms of the interactions between tumor cells and the cellular components of the ovarian cancer peritoneal microenvironment, specifically, mesothelial cells and macrophages. We found that SPARC not only significantly reduced macrophage chemoattractant protein-1 production and its macrophage chemotactic effect, but also attenuated the response of ovarian cancer cells to the mitogenic and proinvasive effects of macrophage chemoattractant protein-1 and decreased macrophage-induced cancer cell invasiveness. Overexpression of SPARC in ovarian cancer cells significantly attenuated macrophage- and mesothelial cell-induced production and activity of interleukin-6, prostanoids (prostaglandins E2 and 8-isoprostanes) as well as matrix metalloproteinases and urokinase plasminogen activator. Moreover, the effects of SPARC overexpression in ovarian cancer cells were mediated, in part, through inhibition of nuclear factor-?B promoter activation. These results indicate, for the first time, that the effects of tumor SPARC as a negative regulator of ovarian cancer are mediated through decreased recruitment of macrophages and downregulation of the associated inflammation.

Original languageEnglish (US)
Pages (from-to)1092-1104
Number of pages13
JournalNeoplasia
Volume10
Issue number10
DOIs
StatePublished - Jan 1 2008

Fingerprint

Ovarian Neoplasms
Cysteine
Inflammation
Macrophages
Proteins
8-epi-prostaglandin F2alpha
Chemotactic Factors
Neoplasms
Tumor Microenvironment
Plasminogen Activators
Urokinase-Type Plasminogen Activator
Cellular Structures
Matrix Metalloproteinases
Dinoprostone
Prostaglandins
Interleukin-6
Down-Regulation
Carcinoma

ASJC Scopus subject areas

  • Cancer Research

Cite this

SPARC ameliorates ovarian cancer-associated inflammation. / Said, Neveen A.; Elmarakby, Ahmed Abdelrazik; Imig, John D.; Fulton, David J; Motamed, Kouros.

In: Neoplasia, Vol. 10, No. 10, 01.01.2008, p. 1092-1104.

Research output: Contribution to journalArticle

Said, Neveen A. ; Elmarakby, Ahmed Abdelrazik ; Imig, John D. ; Fulton, David J ; Motamed, Kouros. / SPARC ameliorates ovarian cancer-associated inflammation. In: Neoplasia. 2008 ; Vol. 10, No. 10. pp. 1092-1104.
@article{dfcf33d6113047b4b7ca0c0458db2a77,
title = "SPARC ameliorates ovarian cancer-associated inflammation",
abstract = "We have recently identified that the role of secreted protein acidic and rich in cysteine (SPARC) in amelioration of peritoneal ovarian carcinomatosis is mediated, at least in part, through mesothelial cell/lysophosphatidic acid-induced inflammatory response in ovarian cancer cells. The aim of this study was to elucidate the molecular mechanisms of the interactions between tumor cells and the cellular components of the ovarian cancer peritoneal microenvironment, specifically, mesothelial cells and macrophages. We found that SPARC not only significantly reduced macrophage chemoattractant protein-1 production and its macrophage chemotactic effect, but also attenuated the response of ovarian cancer cells to the mitogenic and proinvasive effects of macrophage chemoattractant protein-1 and decreased macrophage-induced cancer cell invasiveness. Overexpression of SPARC in ovarian cancer cells significantly attenuated macrophage- and mesothelial cell-induced production and activity of interleukin-6, prostanoids (prostaglandins E2 and 8-isoprostanes) as well as matrix metalloproteinases and urokinase plasminogen activator. Moreover, the effects of SPARC overexpression in ovarian cancer cells were mediated, in part, through inhibition of nuclear factor-?B promoter activation. These results indicate, for the first time, that the effects of tumor SPARC as a negative regulator of ovarian cancer are mediated through decreased recruitment of macrophages and downregulation of the associated inflammation.",
author = "Said, {Neveen A.} and Elmarakby, {Ahmed Abdelrazik} and Imig, {John D.} and Fulton, {David J} and Kouros Motamed",
year = "2008",
month = "1",
day = "1",
doi = "10.1593/neo.08672",
language = "English (US)",
volume = "10",
pages = "1092--1104",
journal = "Neoplasia (United States)",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - SPARC ameliorates ovarian cancer-associated inflammation

AU - Said, Neveen A.

AU - Elmarakby, Ahmed Abdelrazik

AU - Imig, John D.

AU - Fulton, David J

AU - Motamed, Kouros

PY - 2008/1/1

Y1 - 2008/1/1

N2 - We have recently identified that the role of secreted protein acidic and rich in cysteine (SPARC) in amelioration of peritoneal ovarian carcinomatosis is mediated, at least in part, through mesothelial cell/lysophosphatidic acid-induced inflammatory response in ovarian cancer cells. The aim of this study was to elucidate the molecular mechanisms of the interactions between tumor cells and the cellular components of the ovarian cancer peritoneal microenvironment, specifically, mesothelial cells and macrophages. We found that SPARC not only significantly reduced macrophage chemoattractant protein-1 production and its macrophage chemotactic effect, but also attenuated the response of ovarian cancer cells to the mitogenic and proinvasive effects of macrophage chemoattractant protein-1 and decreased macrophage-induced cancer cell invasiveness. Overexpression of SPARC in ovarian cancer cells significantly attenuated macrophage- and mesothelial cell-induced production and activity of interleukin-6, prostanoids (prostaglandins E2 and 8-isoprostanes) as well as matrix metalloproteinases and urokinase plasminogen activator. Moreover, the effects of SPARC overexpression in ovarian cancer cells were mediated, in part, through inhibition of nuclear factor-?B promoter activation. These results indicate, for the first time, that the effects of tumor SPARC as a negative regulator of ovarian cancer are mediated through decreased recruitment of macrophages and downregulation of the associated inflammation.

AB - We have recently identified that the role of secreted protein acidic and rich in cysteine (SPARC) in amelioration of peritoneal ovarian carcinomatosis is mediated, at least in part, through mesothelial cell/lysophosphatidic acid-induced inflammatory response in ovarian cancer cells. The aim of this study was to elucidate the molecular mechanisms of the interactions between tumor cells and the cellular components of the ovarian cancer peritoneal microenvironment, specifically, mesothelial cells and macrophages. We found that SPARC not only significantly reduced macrophage chemoattractant protein-1 production and its macrophage chemotactic effect, but also attenuated the response of ovarian cancer cells to the mitogenic and proinvasive effects of macrophage chemoattractant protein-1 and decreased macrophage-induced cancer cell invasiveness. Overexpression of SPARC in ovarian cancer cells significantly attenuated macrophage- and mesothelial cell-induced production and activity of interleukin-6, prostanoids (prostaglandins E2 and 8-isoprostanes) as well as matrix metalloproteinases and urokinase plasminogen activator. Moreover, the effects of SPARC overexpression in ovarian cancer cells were mediated, in part, through inhibition of nuclear factor-?B promoter activation. These results indicate, for the first time, that the effects of tumor SPARC as a negative regulator of ovarian cancer are mediated through decreased recruitment of macrophages and downregulation of the associated inflammation.

UR - http://www.scopus.com/inward/record.url?scp=54249127338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54249127338&partnerID=8YFLogxK

U2 - 10.1593/neo.08672

DO - 10.1593/neo.08672

M3 - Article

C2 - 18813349

AN - SCOPUS:54249127338

VL - 10

SP - 1092

EP - 1104

JO - Neoplasia (United States)

JF - Neoplasia (United States)

SN - 1522-8002

IS - 10

ER -